ClinicalTrials.gg
CompletedNCT06168409Bax24Updated Aug 6, 2026Results posted

A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

A Phase 3 interventional study of Baxdrostat and Placebo in Resistant Hypertension, sponsored by AstraZeneca. Completed at 102 sites in 22 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing baxdrostat in Hypertension — 2 open to participants now, 4 under way, 3 of them phase 3. baxdrostat · Hypertension.

Enrollment
9th of 18
218 · median 197
Started
2024
with 3 others
Phase 3
6 of 18
2 open now
Registered
12th of 18
by date
Lead sponsor
16 of 18
AstraZeneca

Among the 18 studies testing baxdrostat in Hypertension, this one is the 9th largest by enrollment, is one of 4 that started in 2024, is one of 6 in phase 3, and was the 12th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

2 of the 18 studies testing baxdrostat in Hypertension are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About baxdrostat

baxdrostat: first FDA approval 2026 (BAXFENDY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing baxdrostat in Hypertension, or all of them as a file.
02

Study summary

This is a Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg Baxdrostat vs. placebo, administered QD orally, on the reduction of SBP, measured by average 24-hour ABPM in 212 participants with rHTN (defined as seated SBP ≥ 140 mmHg at Screening and mean ambulatory SBP ≥ 130 mmHg at baseline, despite a stable regimen of ≥ 3 antihypertensive agents, one of which is a diuretic).

Read the detailed description

This is a Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety, tolerability and the effect of 2 mg baxdrostat versus placebo, administered once a day (QD) orally, on the reduction of ambulatory SBP in participants with rHTN, defined as BP targets not being achieved in an individual despite the use of at least 3 antihypertensive agents of different classes (at maximum tolerated dose in the judgement of the Investigator), one of which is a diuretic.

03

Conditions studied

  • Resistant Hypertension

Browse trials for

Keywords

  • Hypertension
  • Resistant hypertension
  • Blood pressure
  • Baxdrostat
  • CIN-107
  • Aldosterone
  • Aldosterone synthase
  • Aldosterone synthase inhibitor
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years old, at the time of signing the .
  • Mean seated SBP on AOBPM of ≥ 140 mmHg and \< 170 mmHg at Screening.
  • Have a stable regimen of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator, for at least 4 weeks prior to screening. Beta blockers used to treat other conditions (ie, migraine, HF, coronary artery disease) should not be counted as an antihypertensive medication for the purpose of qualifying for this study.
  • Have ≥ 45 mL/min/1.73 m2 at Screening.
  • Serum potassium (K+) level ≥ 3.5 and \< 5.0 mmol/L at Screening, determined as per central laboratory
  • Randomization Criteria: mean ambulatory SBP of ≥ 130 mmHg at randomisation.

Exclusion criteria

Exclusion Criteria:

  • Mean seated SBP on AOBPM ≥ 170 mmHg.
  • Mean seated DBP on AOBPM ≥ 110 mmHg.
  • Serum sodium level \< 135 mmol/L at Screening, as per central laboratory.
  • Participant has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation.
  • functional HF class IV.
  • Persistent atrial fibrillation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
218 participants (actual)

Study arms

  • Experimental
    2 mg baxdrostat

    2 mg baxdrostat administered orally, once daily (QD).

    Drug: Baxdrostat

  • Placebo comparator
    Placebo

    Placebo administered orally, once daily (QD)

    Drug: Placebo

Interventions

  • Baxdrostat tablet administered orally, once daily (QD). Unit dose strength: • 2 mg per tablet.

    Also known as: CIN-107

  • DrugPlacebo

    Placebo tablet matching baxdrostat, administered orally, once daily (QD).

06

What researchers measure

Primary outcomes

  1. Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy

    Time frame: Baseline to week 12

Secondary outcomes

  1. Change From Baseline in Ambulatory Night-time Average SBP (mmHg) at Week 12 LS Means

    Time frame: Baseline to week 12

  2. Change From Baseline in Ambulatory Daytime Average SBP (mmHg) at Week 12

    Time frame: Baseline to week 12

  3. Change From Baseline in Seated SBP (mmHg) at Week 12

    Time frame: Baseline to week 12

  4. Achieving Ambulatory 24-hour Average SBP of < 130 mmHg at Week 12

    Time frame: Baseline to week 12

  5. Change From Baseline in Ambulatory 24-hour Average DBP (mmHg) at Week 12

    Time frame: Baseline to week 12

  6. Change From Baseline in Ambulatory Night-time Average DBP (mmHg) at Week 12

    Time frame: Baseline to week 12

  7. Change From Baseline in Ambulatory Daytime Average DBP (mmHg) at Week 12

    Time frame: Baseline to week 12

  8. Change From Baseline in Seated DBP (mmHg) at Week 12

    Time frame: Baseline to week 12

  9. Achieving a Nocturnal SBP Dipping of >= 10% at Week 12

    Time frame: Baseline to week 12

Other outcomes

  1. Least Square Mean Difference for Change From Baseline in Seated SBP at Week 4

    Time frame: Baseline to week 4

  2. Least Square Mean Difference for Change From Baseline in Seated SBP at Week 8

    Time frame: Baseline to week 8

  3. Least Square Mean Difference for Change From Baseline in Seated DBP at Week 4

    Time frame: Baseline to week 4

  4. Least Square Mean Difference for Change From Baseline in Seated DBP at Week 8

    Time frame: Baseline to week 8

07

Results

Posted Aug 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneBaxdrostat 2 mgPlacebo
Started109109
Started study intervention108109
Completed103104
Not completed65
Withdrew: Withdrawal by subject02
Withdrew: Any other reason63

Outcome measures

PrimaryLeast Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy
mmHgBaxdrostat 2 mgPlacebo
Least Square Mean Difference for Change From Baseline in Ambulatory 24-hour Average SBP at Week 12: Treatment Policy Strategy-16.6 (-18.8 to -14.3)-2.6 (-4.7 to -0.4)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -14 · 95% CI -17.2 to -10.8
SecondaryChange From Baseline in Ambulatory Night-time Average SBP (mmHg) at Week 12 LS Means
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Ambulatory Night-time Average SBP (mmHg) at Week 12 LS Means
mmHgBaxdrostat 2 mgPlacebo
Change From Baseline in Ambulatory Night-time Average SBP (mmHg) at Week 12 LS Means-16.0 (-18.6 to -13.4)-2.1 (-4.6 to 0.4)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -13.9 · 95% CI -17.5 to -10.3
SecondaryChange From Baseline in Ambulatory Daytime Average SBP (mmHg) at Week 12
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Ambulatory Daytime Average SBP (mmHg) at Week 12
mmHgBaxdrostat 2 mgPlacebo
Change From Baseline in Ambulatory Daytime Average SBP (mmHg) at Week 12-16.8 (-19.2 to -14.4)-2.7 (-5.1 to -0.4)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -14.1 · 95% CI -17.4 to -10.7
SecondaryChange From Baseline in Seated SBP (mmHg) at Week 12
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated SBP (mmHg) at Week 12
mmHgBaxdrostat 2 mgPlacebo
Change From Baseline in Seated SBP (mmHg) at Week 12-14.9 (-18.2 to -11.6)-4.7 (-7.9 to -1.4)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -10.3 · 95% CI -14.9 to -5.6
SecondaryAchieving Ambulatory 24-hour Average SBP of < 130 mmHg at Week 12
Time frame:
Baseline to week 12
Reported as:
Count of participants · Participants
Achieving Ambulatory 24-hour Average SBP of < 130 mmHg at Week 12
ParticipantsBaxdrostat 2 mgPlacebo
Achieving Ambulatory 24-hour Average SBP of < 130 mmHg at Week 126014
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 15.2 · 95% CI 6.6 to 35.2
SecondaryChange From Baseline in Ambulatory 24-hour Average DBP (mmHg) at Week 12
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Ambulatory 24-hour Average DBP (mmHg) at Week 12
mmHgBaxdrostat 2 mgPlacebo
Change From Baseline in Ambulatory 24-hour Average DBP (mmHg) at Week 12-8.3 (-9.7 to -6.9)-1.5 (-2.9 to -0.1)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -6.8 · 95% CI -8.8 to -4.8
SecondaryChange From Baseline in Ambulatory Night-time Average DBP (mmHg) at Week 12
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Ambulatory Night-time Average DBP (mmHg) at Week 12
mmHgBaxdrostat 2 mgPlacebo
Change From Baseline in Ambulatory Night-time Average DBP (mmHg) at Week 12-7.9 (-9.6 to -6.3)-1.1 (-2.7 to 0.5)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -6.9 · 95% CI -9.1 to -4.6
SecondaryChange From Baseline in Ambulatory Daytime Average DBP (mmHg) at Week 12
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Ambulatory Daytime Average DBP (mmHg) at Week 12
mmHgBaxdrostat 2 mgPlacebo
Change From Baseline in Ambulatory Daytime Average DBP (mmHg) at Week 12-8.4 (-9.9 to -6.9)-1.7 (-3.2 to -0.3)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -6.7 · 95% CI -8.8 to -4.6
SecondaryChange From Baseline in Seated DBP (mmHg) at Week 12
Time frame:
Baseline to week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Seated DBP (mmHg) at Week 12
mmHgBaxdrostat 2 mgPlacebo
Change From Baseline in Seated DBP (mmHg) at Week 12-7.6 (-9.5 to -5.7)-2.6 (-4.5 to -0.7)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -5.0 · 95% CI -7.7 to -2.3
SecondaryAchieving a Nocturnal SBP Dipping of >= 10% at Week 12
Time frame:
Baseline to week 12
Reported as:
Count of participants · Participants
Achieving a Nocturnal SBP Dipping of >= 10% at Week 12
ParticipantsBaxdrostat 2 mgPlacebo
Achieving a Nocturnal SBP Dipping of >= 10% at Week 123628
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · Regression, Logistic · p = 0.1458 · Odds ratio (or): 1.6 · 95% CI 0.9 to 3.0
Other pre-specifiedLeast Square Mean Difference for Change From Baseline in Seated SBP at Week 4
Time frame:
Baseline to week 4
Reported as:
Least squares mean · mmHg
Least Square Mean Difference for Change From Baseline in Seated SBP at Week 4
mmHgBaxdrostat 2 mgPlacebo
Least Square Mean Difference for Change From Baseline in Seated SBP at Week 4-12.1 (-14.8 to -9.4)-1.1 (-3.8 to 1.6)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -11.0 · 95% CI -14.9 to -7.2
Other pre-specifiedLeast Square Mean Difference for Change From Baseline in Seated SBP at Week 8
Time frame:
Baseline to week 8
Reported as:
Least squares mean · mmHg
Least Square Mean Difference for Change From Baseline in Seated SBP at Week 8
mmHgBaxdrostat 2 mgPlacebo
Least Square Mean Difference for Change From Baseline in Seated SBP at Week 8-11.6 (-14.5 to -8.6)-2.4 (-5.4 to 0.6)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -9.2 · 95% CI -13.4 to -5.0
Other pre-specifiedLeast Square Mean Difference for Change From Baseline in Seated DBP at Week 4
Time frame:
Baseline to week 4
Reported as:
Least squares mean · mmHg
Least Square Mean Difference for Change From Baseline in Seated DBP at Week 4
mmHgBaxdrostat 2 mgPlacebo
Least Square Mean Difference for Change From Baseline in Seated DBP at Week 4-5.4 (-7.3 to -3.6)0.1 (-1.8 to 1.9)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -5.5 · 95% CI -8.1 to -2.9
Other pre-specifiedLeast Square Mean Difference for Change From Baseline in Seated DBP at Week 8
Time frame:
Baseline to week 8
Reported as:
Least squares mean · mmHg
Least Square Mean Difference for Change From Baseline in Seated DBP at Week 8
mmHgBaxdrostat 2 mgPlacebo
Least Square Mean Difference for Change From Baseline in Seated DBP at Week 8-6.1 (-7.8 to -4.3)-0.5 (-2.3 to 1.2)
Statistical analysis
  • Baxdrostat 2 mg vs Placebo · ANCOVA · p = <0.0001 · Least-squares mean difference: -5.5 · 95% CI -8.0 to -3.0

Adverse events

Collected over From the day of randomization until week 14, including 12 weeks double blind treatment period and 2 weeks safety follow-up.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baxdrostat 2 mg0/108 (0%)1/108 (0.9%)56/108 (51.9%)
Placebo0/109 (0%)1/109 (0.9%)39/109 (35.8%)
Most frequent serious events
Most frequent serious events
EventBaxdrostat 2 mgPlacebo
Acute kidney injuryRenal and urinary disorders1/1080/109
Thoracic vertebral fractureInjury, poisoning and procedural complications0/1081/109
Most frequent other events
Showing 10 of 104
Most frequent other events
EventBaxdrostat 2 mgPlacebo
HyperkalaemiaMetabolism and nutrition disorders11/1083/109
HeadacheNervous system disorders6/1083/109
HypotensionVascular disorders5/1080/109
HypokalaemiaMetabolism and nutrition disorders0/1085/109
HypertensionVascular disorders0/1084/109
DiarrhoeaGastrointestinal disorders3/1081/109
FatigueGeneral disorders3/1081/109
Influenza like illnessGeneral disorders3/1081/109
InfluenzaInfections and infestations3/1080/109
Urinary tract infectionInfections and infestations3/1080/109

Baseline characteristics

Age, Continuous
Age, Continuous(Age (years))Baxdrostat 2 mgPlaceboTotal
Age (years)59.4 ± 11.259.7 ± 12.459.6 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Baxdrostat 2 mgPlaceboTotal
Female383977
Male7070140
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baxdrostat 2 mgPlaceboTotal
American Indian or Alaska Native000
Asian161935
Native Hawaiian or Other Pacific Islander000
Black or African American4610
White8684170
More than one race101
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(Participants)Baxdrostat 2 mgPlaceboTotal
ARG121325
AUS268
BEL011
BGR81119
CAN044
CZE6410
DEU213
ESP538
GBR9918
GRC71017
HUN303
MYS303
PHL123
POL8513
SAU336
SVK213
THA448
TUR10919
TWN426
USA151227
VNM279
ZAF224
08

Study locations

102 sites
  • Research Site
    Surprise, Arizona 85374, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site
    Lake Worth, Florida 33467, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Lexington, Kentucky 40503, United States
  • Research Site
    The Bronx, New York 10455, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Jacksonville, North Carolina 28546, United States
  • Research Site
    Kinston, North Carolina 28504, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Langhorne, Pennsylvania 19047, United States
  • Research Site
    Brownsville, Texas 78526, United States
  • Research Site
    Corpus Christi, Texas 78404, United States
  • Research Site
    Lampasas, Texas 76550, United States
  • Research Site
    CABA, C1061, Argentina
  • Research Site
    CABA, C1425HFA, Argentina
  • Research Site
    Capital Federal, C1060ABN, Argentina
  • Research Site
    Córdoba, X5003DCP, Argentina
  • Research Site
    Lanús Este, B1824KAJ, Argentina
  • Research Site
    Rosario, S2000PBJ, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    San Vicente, 5006, Argentina
  • Research Site
    Clayton, 3168, Australia
  • Research Site
    Perth, 6000, Australia
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Sofia, 1618, Bulgaria
  • Research Site
    Sofia, 1680, Bulgaria
  • Research Site
    Edmonton, Alberta T6G 2C8, Canada
  • Research Site
    North Vancouver, British Columbia V7M 2H4, Canada
  • Research Site
    Cambridge, Ontario N1R 6V6, Canada
  • Research Site
    Toronto, Ontario M6G 1M2, Canada
  • Research Site
    Waterloo, Ontario N2T 0C1, Canada
  • Research Site
    Chicoutimi, Quebec G7H 7K9, Canada
  • Research Site
    Terrebonne, Quebec J6X 4P7, Canada
  • Research Site
    Benešov, 256 01, Czechia
  • Research Site
    Brandýs nad Labem, 250 01, Czechia
  • Research Site
    Broumov, 55001, Czechia
  • Research Site
    Louny, 440 01, Czechia
  • Research Site
    Bad Homburg, 61348, Germany
  • Research Site
    Berlin, 12203, Germany
  • Research Site
    Frankfurt, 60590, Germany
  • Research Site
    Kaiserslautern, 67655, Germany
  • Research Site
    Athens, 11527, Greece
  • Research Site
    Attica, 11527, Greece
  • Research Site
    Thessaloniki, 54642, Greece
  • Research Site
    Budapest, 1115, Hungary
  • Research Site
    Budapest, 1148, Hungary
  • Research Site
    Kalocsa, 6300, Hungary
  • Research Site
    Nyíregyháza, 4400, Hungary
  • Research Site
    Pécs, 7635, Hungary
  • Research Site
    Kota Bharu, 15586, Malaysia
  • Research Site
    Muar town, 84000, Malaysia
  • Research Site
    Sarawak Miri, 98000, Malaysia
  • Research Site
    Angeles City, 2009, Philippines
  • Research Site
    Iloilo City, 5000, Philippines
  • Research Site
    Bialystok, 15-540, Poland
  • Research Site
    Gdansk, 80-214, Poland
  • Research Site
    Krakow, 30-688, Poland
  • Research Site
    Lodz, 91-002, Poland
  • Research Site
    Poznan, 61-848, Poland
  • Research Site
    Warsaw, 04-628, Poland
  • Research Site
    Riyadh, 11426, Saudi Arabia
  • Research Site
    Riyadh, 11462, Saudi Arabia
  • Research Site
    Brezno, 977 01, Slovakia
  • Research Site
    Košice, 04022, Slovakia
  • Research Site
    Svidník, 08901, Slovakia
  • Research Site
    Cape Town, 7500, South Africa
  • Research Site
    Durban, 4001, South Africa
  • Research Site
    Barcelona, 08003, Spain
  • Research Site
    Barcelona, 08036, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Santa Coloma de Gramenet, 08923, Spain
  • Research Site
    Terrassa (Barcelona), 08221, Spain
  • Research Site
    Valencia, 46010, Spain
  • Research Site
    New Taipei City, 220, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Bangkok, 10330, Thailand
  • Research Site
    Bangkok, 10400, Thailand
  • Research Site
    Bangkok, 10700, Thailand
  • Research Site
    Chiang Mai, 50200, Thailand
  • Research Site
    Khon Kaen, 40002, Thailand
  • Research Site
    Adana, 01060, Turkey (Türkiye)
  • Research Site
    Ankara, 06230, Turkey (Türkiye)
  • Research Site
    Kahramanmaraş, 46100, Turkey (Türkiye)
  • Research Site
    Kayseri, 38039, Turkey (Türkiye)
  • Research Site
    Odunpazari, 26080, Turkey (Türkiye)
  • Research Site
    Corby, NN17 2UR, United Kingdom
  • Research Site
    London, E1 1BB, United Kingdom
  • Research Site
    London, W6 7HY, United Kingdom
  • Research Site
    Prescot, L35 5DR, United Kingdom
  • Research Site
    Swindon, SN3 6BB, United Kingdom
  • Research Site
    Thetford, IP24 1JD, United Kingdom
  • Research Site
    Weston-super-Mare, BS24 7PR, United Kingdom
  • Research Site
    Yate, BS37 4AX, United Kingdom
  • Research Site
    Hanoi, 100000, Vietnam

Showing the first 100 of 102 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Azizi M, Brown JM, Dwyer JP, Flack JM, Jones ESW, Kurlyandskaya R, Li H, Birve F, Lihn AS, Perl S, Schlaich MP, Shibata H, Wang JG, Williams B; Bax24 investigators. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2026 Mar 7;407(10532):988-999. doi: 10.1016/S0140-6736(25)02549-8. PubMed 41794437 ↗
  • Dwyer JP, Maklad N, Vedin O, Monyak J, Myte R, Chertow GM, Heerspink HJL, Little DJ. Efficacy and Safety of Baxdrostat in Participants with CKD and Uncontrolled Hypertension: A Randomized, Double-Blind, Placebo-Controlled Trial. J Am Soc Nephrol. 2026 Feb 1;37(2):299-311. doi: 10.1681/ASN.0000000849. Epub 2025 Sep 6. PubMed 40913594 ↗
  • Flack JM, Azizi M, Brown JM, Dwyer JP, Jones ESW, Lihn AS, Liu L, Olsson DS, Perl S, Shibata H, Wang JG, Wilderang U, Wittes JT, Williams B. Baxdrostat for uncontrolled and resistant hypertension: rationale and design of the Phase 3 clinical trials BaxHTN, BaxAsia, and Bax24. Hypertens Res. 2025 Nov;48(11):2911-2923. doi: 10.1038/s41440-025-02297-7. Epub 2025 Aug 25. PubMed 40850955 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2025, 17 months.

Results were first posted in Aug 2026, 11 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 17 months is close to that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2023
First posted
Dec 13, 2023
StartActual
Mar 1, 2024
Primary completionActual
Aug 17, 2025
CompletionActual
Aug 17, 2025
Results first posted
Aug 6, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06168409
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Dec 13, 2023
Start date
Mar 1, 2024
Primary completion
Aug 17, 2025
Completion
Aug 17, 2025
Results posted
Aug 6, 2026
Last update
Aug 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baxdrostat

Start the discussion